Impact of Comorbid Conditions on Linaclotide Treatment Outcomes in Adults With CIC or IBS-C and Pediatric Patients With FC: A Post Hoc Analysis of Phase 3 Clinical Trial Data (ACG 2026) - Aug 29, 2026 - Abstract #P3083A; Pres time: Oct 12, 2026; 10:30 AM - 04:15 PM; Location: Exhibit Halls A - D (Level 3); P3, P3b | "In adult (n=5193) and pediatric (6â17 years; n=328) pts, 56.0% and 13.7% had â¥1 comorbidity, respectively: those with (vs without) comorbidities were slightly older and more often female; other BL characteristics were comparable ( Table ). Treatment with LIN (vs PBO) improved SBM/week and CSBM/week across all comorbidity subgroups . In adults, i mprovements were seen in stool consistency, abdominal pain and bloating, regardless of BL comorbidity status ( Figure )."
Clinical • P3 data • Retrospective data • CNS Disorders • Constipation • Depression • Discoid Lupus Erythematosus • Dyspepsia • Endometriosis • Fibromyalgia • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Gynecology • Immunology • Inflammatory Arthritis • Lupus • Migraine • Mood Disorders • Musculoskeletal Pain • Myositis • Pediatrics • Rheumatoid Arthritis • Systemic Lupus Erythematosus • Women's Health
|
|
Kyle Staller MD MPH 1; Christopher V. Almario MD MSHPM 2; Xiao Jing Wang MD 3; Morgan Sendzischew Shane MD 4; Linda Nguyen MD 5; Charlotte Dancey PhD 6; Sally Higgins PharmD 7; Annie Cheung PharmD 7; James Wu PhD 7
|